Enter your Email Address


Useful Links

Know What The Insiders Are Doing!
Stock Trading Software

More Links




[Most Recent Quotes from www.kitco.com]

[Most Recent Quotes from www.kitco.com]




MVIS, NBIX, GVBP, DrStockPick.com Watch List! for Wednesday September 16, 2009, Microvision, Inc., Neurocrine Biosciences Inc. and GENova Biotherapeutics Inc., GVBP.OB

Dr. Stock Pick (September 15th, 2009) Writes:

Dr Stock Pick HOT News & Alerts!

_______________________________________

drstock-2-3

FREE Daily Stock Alerts From DrStockPick.com

signup3m

_______________________________________

DrStockPick.com Watch List!

My Picks for Wednesday September 16, 2009, are:

**************************************************************

MVIS, Microvision, Inc.

MVIS is a global leader in innovative ultra-miniature projection display and image capture products for mobility applications

Today was the commercial introduction of the world’s first laser-based pico projector, called SHOW WX™, based on its proprietary PicoP® display engine technology.

The MVIS pico projector uses the revolutionary laser-based PicoP display engine that delivers large, colorful, bright, and vivid images that are always in focus, regardless of projection distance. The accessory product is a simple plug-n-play pico projector for people on-the-go who

...

Osteologix, Inc. (OLGX.OB) Receives Positive Patent Decision for Key Osteoporosis Drug in Japan

QualityStocks (August 25th, 2009) Writes:

Osteologix, Inc., a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, yesterday announced that the company has been informed that a positive decision was made in Japan to grant a patent for a key osteoporosis drug. The Japan Patent Office (JPO) has issued Osteologix, Inc. a decision to grant a patent for application number 2006-504379: “Treating Cartilage/Bone Conditions with Water-Soluble Strontium Salts.”

The patent is for NB S101 (strontium malonate), the company’s lead osteoporosis drug candidate. Osteologix expects that the patent will be issued by the end of 2009 with a 20-year term that will expire in 2024. Osteologix has now received patent protection for its novel osteoporosis therapy in the three major pharmaceutical markets, including Europe, the United States and Japan.

Philip J. Young, the president and CEO of Osteologix, stated, “We believe the intellectual property protections established by this patent in Japan,

...

Beacon Equity Research Featured Client: Medivisor Inc. (MVSR.PK)

QualityStocks (November 10th, 2008) Writes:

Medivisor Inc. is a medical communications company dedicated to providing concise and timely medical information to healthcare industry professionals. Headquartered in Huntington Station, New York, the Company exclusively serves the bioscience and pharmaceutical markets. They offer specialized medical marketing consulting, graphic design, web site marketing strategy, and market research.

Medivisor provides concise and timely medical information through the internet on advances in medicine and changes within the industry. They also utilize sales representatives who make periodic visits to healthcare providers. The Company’s business model provides a cost effective, efficient way to make medical personnel aware of opportunities, tools, information, and resources available to them as part of their patient care. Medivisor also collaborates with pharmaceutical distribution companies to market and grow sales of new and current drugs. This aids in lowering current marketing costs and helps to bring products and services to market.

Medivisor reached an exclusive marketing and distribution agreement with

...

Lilly – Aside from ImClone Rumors – Analyst Blog

Zacks Market Commentaries (October 3rd, 2008) Writes:
Eli Lilly and Company (LLY) is a global healthcare company with core products in a number of primary-care pharmaceutical markets. The leading product is Zyprexa, a treatment for schizophrenia and bipolar disorder. The company's other leading drugs include Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Byetta (type-II diabetes), Cialis (erectile dysfunction), Strattera (ADHD), and Alimta (chemotherapy).The company is entering a challenging period, brought about by recent pipeline disappointments, most notably uncertainty surrounding antiplatelet drug Prasugrel. Although we believe the underlying fundamentals of the company remain solid, the recent pipeline setbacks and lack of clarity surrounding prasugrel will likely limit the upside to the stock. We also believe that sales of Zyprexa will begin to decline in 2008 as generic Risperdal eats into market share. We see little movement in the stock until the above issues are addressed. We rate the shares a Hold with ...

Quality Systems (QSII) and Robbins & Myers (RBN) “Trading Transparency”

Bob Freedland (September 11th, 2008) Writes:

Hello Friends!  Thanks so much for stopping by and visiting my blog, Stock Picks Bob’s Advice!  As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website.

One of the strongest stocks in my portfolio the past two months has been Quality Systems (QSII).   After purchasing this at a cost basis of approximately $38.18 just last month on August 8, 2008, the stock has moved sharply higher.  QSII closed today at $44.89, well above my purchase price, but down $(2.15) or (4.57)% on the day.

Earlier today, with the market turning higher after a sell-off, I found myself seeing QSII moving sharply lower, lagging the rest of the portfolio.

Although the fundamentals remain …

Unigene Labs Inc. (UGNE.OB) Breaks Ground on New Biotechnology Plant, Eye’s Chinese Peptide Market

QualityStocks (July 7th, 2008) Writes:

Having a “white knight” hanging around to give your company a nice infusion of cash is always a nice incentive to taking a bit of a risk. New market entry is always a bit of a risk, even if you have an established product to enter that market with. Not being 100% sure of how that new market will react – socially and financially - to a new product is always the risk. But if the “white knight” is willing to support in more than just a monetary way, the chances of sizable profit can be increased considerably.

Unigene Labs Inc., a biopharmaceutical company, works to develop and market peptide and other related pharmaceuticals. The company currently has an estimated 55% market share of the prescription nasal congestion marketplace and is entering Phase III trials with a new calcintonin product.

The company has been having moderate successes with its Fortical product, although

...

Newsletter

No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.